Show simple item record

dc.contributor.authorRosiou, K
dc.contributor.authorOng Ming San, E
dc.contributor.authorKumar, Aditi
dc.contributor.authorEsquivel, Kim
dc.contributor.authorAlmas, Saima
dc.contributor.authorStokes, Daniel
dc.contributor.authorNg, Tze
dc.contributor.authorJayasooriya, Nishani
dc.contributor.authorRanasinghe, Ian
dc.contributor.authorPollok, Richard
dc.contributor.authorBrookes, Matthew
dc.contributor.authorSelinger, Christian
dc.date.accessioned2022-04-25T09:46:42Z
dc.date.available2022-04-25T09:46:42Z
dc.date.issued2021-09-23
dc.identifier.citationRosiou K, Ong Ming San E, Kumar A, Esquivel K, Almas S, Stokes D, Ng T, Jayasooriya N, Ranasinghe I, Pollok R, Brookes M, Selinger CP. (2021) Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study. Journal of Clinical Medicine, 10(19):4329. https://doi.org/10.3390/jcm10194329en
dc.identifier.issn2077-0383en
dc.identifier.pmid34640345 (pubmed)
dc.identifier.doi10.3390/jcm10194329en
dc.identifier.urihttp://hdl.handle.net/2436/624716
dc.description© 2021 The Authors. Published by MDPI. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.3390/jcm10194329en
dc.description.abstractDuring the COVID‐19 pandemic many IBD units chose Budesonide MMX (Cortiment) as the first‐line treatment for flares of ulcerative colitis (UC) in outpatients for its favourable side effect profile. This retrospective study of all UC patients treated with oral steroids between 1 March 2019– 30 June 2019 and 1 March 2020–30 June 2020 aimed to compare Cortiment with Prednisolone in routine clinical practice. Outcomes included the need for hospitalisation for acute severe ulcerative colitis, symptoms at four weeks and end of treatment, and the need for rescue Prednisolone. The 2019 and 2020 cohorts did not differ at the baseline. Cortiment prescriptions rose from 24.5% in 2019 to 70.1% in 2020 (p < 0.001). At week four there were significant differences between 2019 and 2020 in mean bowel frequency (3.49 vs. 5.85, p = 0.001), rectal bleeding <50% (89.7% vs. 73.1% of patients, p = 0.039), and physician global assessment (PGA) (39.2% vs. 19.8% in remission, p = 0.045). There was no significant difference in hospital admissions, rectal bleeding, and PGA at week eight. Rescue Prednisolone was required in 10% of Cortiment patients in 2019 vs. 31.3% in 2020 (p = 0.058). Active IBD is associated with worse COVID‐19 outcomes prompting the careful evaluation of the choice of first‐line steroid for UC, as Cortiment was associated with worse outcomes at four weeks.en
dc.formatapplication/pdfen
dc.languageeng
dc.language.isoenen
dc.publisherMDPIen
dc.rightsLicence for published version: Creative Commons Attribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectulcerative colitisen
dc.subjectinflammatory bowel diseaseen
dc.subjectprednisoloneen
dc.subjectBudesonide MMXen
dc.subjectCortimenten
dc.subjectCOVID-19en
dc.titleComparative outcomes of budesonide mmx versus prednisolone for ulcerative colitis: Results from a British retrospective multi‐centre real‐world studyen
dc.typeJournal articleen
dc.identifier.eissn2077-0383
dc.identifier.journalJournal of Clinical Medicineen
dc.date.updated2022-04-22T07:01:49Z
dc.contributor.institutionLeeds Gastroenterology Institute, Leeds Teaching Hospitals, Leeds LS9 7TF, UK.
pubs.place-of-publicationSwitzerland
dc.date.accepted2021-09-20
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.project25042022MBen
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2022-04-25en
dc.source.volume10
dc.source.issue19
dc.source.beginpage4329
dc.source.endpage4329
dc.description.versionPublished version
refterms.dateFCD2022-04-25T09:46:32Z
refterms.versionFCDVoR
refterms.dateFOA2022-04-25T09:46:43Z


Files in this item

Thumbnail
Name:
Comparative Outcomes of Budesonide ...
Size:
222.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Licence for published version: Creative Commons Attribution 4.0 International
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International